Cumulative incidence of outcomes in each severity group at 3, 6, 12 and 24 months*
| Outcome | Kaplan-Meier cumulative incidence, % (95% CI) | ||||
| 3 months | 6 months | 12 months | 24 months | ||
| Composite outcome | Group 1, most severe | 48 (47 to 49) | 57 (57 to 58) | 67 (66 to 68) | 76 (75 to 77) |
| Group 2, moderate severity | 7.6 (7.3 to 8.0) | 12 (11 to 12) | 17 (16 to 17) | 25 (24 to 25) | |
| Group 3, least severe | 11 (10 to 11) | 15 (15 to 15) | 21 (20 to 21) | 28 (28 to 29) | |
| Recorded mortality | Group 1, most severe | 5.0 (4.6 to 5.4) | 7.2 (6.7 to 7.7) | 11 (10 to 11) | 18 (17 to 18) |
| Group 2, moderate severity | 3.6 (3.4 to 3.8) | 5.7 (5.4 to 6.1) | 8.5 (8.2 to 8.9) | 13 (13 to 14) | |
| Group 3, least severe | 6.6 (6.3 to 6.9) | 9.4 (9.0 to 9.8) | 13 (13 to 14) | 18 (18 to 19) | |
| Variceal haemorrhage | Group 1, most severe | 41 (40 to 42) | 48 (47 to 49) | 55 (54 to 56) | 62 (61 to 63) |
| Group 2, moderate severity | 1.1 (1.0 to 1.2) | 1.7 (1.5 to 1.9) | 2.5 (2.3 to 2.7) | 4.0 (3.7 to 4.3) | |
| Group 3, least severe | 0.4 (0.3 to 0.5) | 0.6 (0.5 to 0.7) | 1.0 (0.8 to 1.1) | 1.7 (1.5 to 1.9) | |
| Hepatic encephalopathy | Group 1, most severe | 10 (9.5 to 11) | 15 (14 to 16) | 22 (21 to 23) | 32 (31 to 33) |
| Group 2, moderate severity | 3.8 (3.5 to 4.0) | 5.9 (5.6 to 6.3) | 8.8 (8.4 to 9.2) | 13 (13 to 14) | |
| Group 3, least severe | 4.8 (4.5 to 5.1) | 6.6 (6.3 to 7.0) | 9.4 (9.0 to 9.8) | 13 (13 to 14) | |
| Complications of ascites | Group 1, most severe | 2.5 (2.2 to 2.8) | 3.6 (3.3 to 4.0) | 5.7 (5.3 to 6.2) | 9.7 (9.1 to 10) |
| Group 2, moderate severity | 0.9 (0.8 to 1.1) | 1.6 (1.4 to 1.7) | 2.2 (2.0 to 2.5) | 3.4 (3.1 to 3.7) | |
| Group 3, least severe | 1.2 (1.1 to 1.4) | 1.8 (1.6 to 2.0) | 2.6 (2.4 to 2.8) | 3.5 (3.2 to 3.8) | |
Due to limitation of the TriNetX platform, no adjustments have been made for competing risks.
*The run date for this analysis was 1–8 February 2023.